A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis (ISLAND2)
A Single Arm, Multicenter, Open-label, Phase 1b Study to Assess the Safety and Tolerability of Oral Vismodegib in Combination With Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Phase
Phase
- Phase 1
Kontakte und Standorte
Studienorte
-
-
-
Hannover, Deutschland, 30625
- Fraunhofer-Institut für Toxikologie und Experimentelle Medizin ITEM
-
-
-
-
California
-
La Jolla, California, Vereinigte Staaten, 92037
- Scripps Clinic
-
-
Florida
-
Orlando, Florida, Vereinigte Staaten, 32803
- Central Florida Pulmonary Group, PA
-
-
Illinois
-
Elk Grove, Illinois, Vereinigte Staaten, 60007
- Suburban Lung Associates
-
-
Indiana
-
Muncie, Indiana, Vereinigte Staaten, 47303
- Medical Consultants, PC ; Pulmonary
-
-
Kentucky
-
Louisville, Kentucky, Vereinigte Staaten, 40202-1798
- University of Louisville
-
-
Louisiana
-
New Orleans, Louisiana, Vereinigte Staaten, 70112
- Tulane University Medical School
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02135
- Steward St. Elizabeth's Medical Center ; Pulmonary, Critical Care and Sleep Medicine
-
-
Nebraska
-
Omaha, Nebraska, Vereinigte Staaten, 68131
- Creighton University Medical Center
-
-
Nevada
-
Reno, Nevada, Vereinigte Staaten, 89503
- Allied Clinical Research
-
-
New Jersey
-
Summit, New Jersey, Vereinigte Staaten, 07901
- Atlantic Respiratory Institute
-
-
North Carolina
-
Greensboro, North Carolina, Vereinigte Staaten, 27403
- Pulmonix LLC
-
Wilmington, North Carolina, Vereinigte Staaten, 28401
- PMG Research of Wilmington
-
-
Washington
-
Everett, Washington, Vereinigte Staaten, 98208
- Western Washington Medical Group
-
Seattle, Washington, Vereinigte Staaten, 98122
- Swedish Medical Center
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Have a diagnosis of IPF 5 years from time of screening, confirmed at baseline
- Tolerated dose of pirfenidone 1602-2403 mg once daily (QD) for a minimum of 24 weeks required prior to and during screening
- Greater than or equal to (>=) 50 percent (%) and less than or equal to (<=) 100% of predicted forced vital capacity (FVC) at screening
- Stable baseline lung function as evidenced by a difference of less than (<) 10% in absolute FVC measurements (in liters) between screening and Day 1/Visit 2 prior to enrollment
- >=30% and <=90% of predicted diffusion capacity of the lung for carbon monoxide at screening
- Agree to use protocol defined methods of contraception
- Male participants must agree not to donate semen during the study and for at least 2 months (or as per local requirements) after the last dose of vismodegib
- Agree not to donate blood or blood products during the study and for at least 9 months (or as per local requirements) after the last dose of study treatment
Exclusion Criteria:
- Prior treatment with vismodegib or any Hh-pathway inhibitor
- Evidence of other known causes of interstitial lung disease
- Hospitalization due to an exacerbation of IPF within 4 weeks prior to or during screening
- Lung transplant expected within 6 months of screening
- Evidence of clinically significant lung disease other than IPF
- Post-bronchodilator forced expiratory volume in 1 second/FVC ratio <0.7 at screening
- Any clinically significant medical disease (other than IPF) that is associated with an expected survival of <6 months, likely to require a change in therapy during the study
- Class IV New York Heart Association chronic heart failure or historical evidence of left ventricular ejection fraction <35%
- Known current malignancy or current evaluation for a potential malignancy
- Known immunodeficiency, including, but not limited to, human immunodeficiency virus infection
- Evidence of acute or chronic hepatitis or known liver cirrhosis
- Creatinine clearance <=30 milliliter per minute, calculated using the Cockcroft-Gault formula
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Vismodegib and Pirfenidone
Participants being treated with pirfenidone, will receive vismodegib 150 milligrams (mg) once daily and pirfenidone up to 2403 mg daily orally for 24 weeks.
|
Pirfenidone will be administered as per the dosage schedule mentioned in arm description.
Andere Namen:
Vismodegib will be administered as per the dosage schedule mentioned in arm description.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percentage of Participants with Serious and Non-Serious Adverse Events
Zeitfenster: Baseline up to 28 weeks
|
An adverse event is any untoward medical occurrence in a participant who receive study drug without regard to possibility of causal relationship.
A serious adverse event is an adverse event resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
|
Baseline up to 28 weeks
|
|
Percentage of Participants with Discontinuation of Any Study Medication Due to a Drug-Related Adverse Event
Zeitfenster: Baseline up to 28 weeks
|
An adverse event is any untoward medical occurrence in a participant who receive study drug without regard to possibility of causal relationship.
Relatedness to the study drug will be assessed by the investigator.
|
Baseline up to 28 weeks
|
|
Percentage of Participants with Dose Modifications Due to Laboratory Abnormalities and Adverse Events
Zeitfenster: Baseline up to 28 weeks
|
An adverse event is any untoward medical occurrence in a participant who receive study drug without regard to possibility of causal relationship.
|
Baseline up to 28 weeks
|
|
Percentage of Participants with Clinically Meaningful Laboratory Abnormalities as Assessed by Investigator
Zeitfenster: Baseline up to 28 weeks
|
Vital signs and laboratory parameters will be evaluated, and percentage of participants with any clinically meaningful abnormalities as assessed by Investigator will be reported.
Laboratory abnormalities of National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Grade greater than (>) 3 will be considered clinical meaningful.
|
Baseline up to 28 weeks
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Total and Free Trough Plasma Concentrations of Vismodegib at Week 4 (Cmin, Wk4)
Zeitfenster: Predose (0 hour) at Week 4
|
Total plasma concentration of vismodegib = free (unbound) vismodegib plasma concentration + alpha-1-acid glycoprotein (AAG)-bound vismodegib plasma concentration.
|
Predose (0 hour) at Week 4
|
|
Total and Free Trough Plasma Concentrations of Vismodegib at Week 12 (Cmin, Wk12)
Zeitfenster: Predose (0 hour) at Week 12
|
Total plasma concentration of vismodegib = free (unbound) vismodegib plasma concentration + AAG-bound vismodegib plasma concentration.
|
Predose (0 hour) at Week 12
|
|
Total and Free Trough Plasma Concentrations of Vismodegib at Week 24 (Cmin, Wk24)
Zeitfenster: Predose (0 hour) at Week 24
|
Total plasma concentration of vismodegib = free (unbound) vismodegib plasma concentration + AAG-bound vismodegib plasma concentration.
|
Predose (0 hour) at Week 24
|
|
Total and Free Trough Plasma Concentrations of Vismodegib at Safety Follow-up Visit (Cmin, SFU)
Zeitfenster: At Day 30 post last dose (last dose = 24 weeks) (up to 28 weeks)
|
Total plasma concentration of vismodegib = free (unbound) vismodegib plasma concentration + AAG-bound vismodegib plasma concentration.
|
At Day 30 post last dose (last dose = 24 weeks) (up to 28 weeks)
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
Studienabschluss (Tatsächlich)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Pathologische Prozesse
- Erkrankungen der Atemwege
- Lungenkrankheit
- Fibrose
- Lungenfibrose
- Idiopathische Lungenfibrose
- Physiologische Wirkungen von Arzneimitteln
- Agenten des peripheren Nervensystems
- Analgetika
- Agenten des sensorischen Systems
- Entzündungshemmende Mittel, nichtsteroidal
- Analgetika, nicht narkotisch
- Entzündungshemmende Mittel
- Antirheumatika
- Antineoplastische Mittel
- Pirfenidon
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- GB29764
- 2015-003481-81 (EudraCT-Nummer)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .